Saturday 17 October 2026
Export DOCS’s income statement to Excel — free account
Doximity, Inc.
DOCS Healthcare Health Information Services
Doximity, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $644.9 million, up 13.1% from fiscal 2025. In the quarter to June 2026, revenue grew 7.34%, EPS fell 53.6% and free cash flow fell 34.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
30.97
0.53
−1.68%
Follow DOCS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
23.30 | 22.40 | 34.87 | 54.59 |
+8 more quarters Free account |
P/S ratio |
5.78 | 6.76 | 13.02 | 22.10 | |
P/FCF ratio |
12.75 | 13.72 | 27.02 | 43.99 | |
P/Operating CF |
90.18 | 39.79 | 136.33 | 146.16 | |
P/B ratio |
4.13 | 4.58 | 8.48 | 12.53 | |
Price to Tangible BV |
4.75 | 5.25 | 9.69 | 14.13 | |
EV/Sales |
4.73 | 5.60 | 11.86 | 20.69 | |
EV/EBITDA |
14.20 | 15.34 | 29.65 | 49.52 | |
EV/Operating CF |
10.12 | 11.05 | 23.99 | 40.20 | |
EV/FCF |
10.43 | 11.36 | 24.62 | 41.18 | |
Quick Ratio |
5.76 | 5.76 | 5.95 | 7.18 | |
Current Ratio |
6.08 | 6.09 | 6.63 | 7.79 | |
Net Debt/EBITDA |
(16.51) | (23.37) | (9.59) | (12.95) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.57 | 0.54 | 0.55 | 0.52 | |
Operating CF/Net income |
1.73 | 5.73 | 0.99 | 1.51 | |
Capex/Depreciation |
(0.30) | (0.31) | (0.50) | (0.57) | |
Research and Development Expense of Revenue |
24.57% | 26.90% | 18.69% | 17.92% | |
Selling, General and Administrative Expense of Revenue |
38.82% | 42.67% | 32.35% | 34.55% | |
Intangible Assets out of Total Assets |
0.11 | 0.11 | 0.11 | 0.10 | |
Share Based Compensation of Revenue |
23.47% | 25.27% | 18.13% | 17.49% | |
Graham Net Nets |
0.20 | 0.18 | 0.10 | 0.07 | |
Graham Number |
10.02 | 10.91 | 12.22 | 13.27 | |
Earnings Yield |
4.29% | 4.46% | 2.87% | 1.83% | |
Free Cash Flow Yield |
7.84% | 7.29% | 3.70% | 2.27% | |
Revenue per Share |
0.86 | 0.78 | 0.99 | 0.90 | |
Operating CF per Share |
0.23 | 0.59 | 0.32 | 0.50 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.22 | 0.57 | 0.31 | 0.49 | |
Cash per Share |
3.77 | 4.00 | 3.92 | 4.68 | |
Shareholders Equity per Share |
5.02 | 5.08 | 5.22 | 5.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.02 | 5.08 | 5.22 | 5.84 | |
Free Cash Flow |
39.60 | 107.27 | 58.52 | 91.58 | |
Working Capital |
763.62 | 789.29 | 843.61 | 951.93 | |
Capital Expenditures |
(2.38) | (2.25) | (2.37) | (2.37) | |
Net Current Asset Value |
746.20 | 771.41 | 815.73 | 930.62 | |
EV/EBIT |
15.97 | 16.79 | 31.69 | 52.07 | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.01 | |
Price to Operating Income |
19.51 | 20.27 | 34.77 | 55.63 | |
| Other line items | |||||
Average Receivables |
159.62 | 136.57 | 147.05 | 127.05 | |
Average Payables |
4.23 | 2.68 | 3.21 | 3.58 | |
Average Assets |
1,144.15 | 1,194.00 | 1,164.59 | 1,187.81 | |
Average Common Equity |
970.83 | 1,016.73 | 1,005.21 | 1,028.36 |
Columns are period end dates